Results 31 to 40 of about 6,639,831 (259)
Advances on TGF-β/Smad signal pathway in hepatic fibrosis
生物医学转化, 2021 The transforming growth factor-β (TGF-β) signaling pathway plays a vital role in regulating cell processes. As far as the liver is concerned, the TGF-β signaling pathway runs through liver diseases, from theinitial liver cell injury to inflammation ...
Han Daoning, Su Xiulan
doaj +1 more source
Dose adaptation of drugs in patients with liver disease [PDF]
, 2009 A detailed introduction into the topic was obtained by developing a German-language online course named “Dose adjustment in Patients with Liver Disease” for the “Swiss Virtual Campus” in collaboration with PNN AG, a spin-off company of the ETH Zurich.
Schlatter-Häner, Chantal
core +1 more source
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. [PDF]
, 2010 The main objectives of this study were to define the occurrence and levels of hepatitis B virus (HBV) DNA in asymptomatic HBV carriers, cirrhosis patients and hepatocellular carcinoma (HCC) cases from The Gambia, and to evaluate the risk for cirrhosis or
Whittle, H +23 more
core +1 more source
Scientific Reports, 2017 Fatty-acid-binding proteins (FABPs) are small intracellular proteins that coordinate lipid-mediated processes by targeting metabolic and immune response pathways.
Isabel Graupera +16 more
doaj +1 more source
Dose adaptation of drugs in patients with liver disease [PDF]
, 2004 In my thesis I defined strategies for dosage adaptation of drugs in patients with liver disease. The major goal of the thesis was to classify antineoplastic drugs and central nervous agents according to pharmacokinetic principles (hepatic extraction and ...
Tchambaz, Lydia
core +1 more source
Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Aim. This paper is aimed at reviewing existing literature that investigates the role of angiogenesis in portal hypertension pathogenesis in liver cirrhosis and the possibilities of its antiangiogenic therapy, along with the description of angiogenesis ...
D. V. Garbuzenko
doaj +1 more source
T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation [PDF]
, 1992 Primary biliary cirrhosis (PBC) is considered an autoimmune disease characterized by destruction of small intrahepatic bile ducts by lymphocytes. Altered functions of these lymphocytes might reflect an abnormal immune response leading to tissue damage ...
Eisenburg, Josef +9 more
core +1 more source
Ketorolac pharmacokinetics in experimental cirrhosis by bile duct ligation in the rat
Annals of Hepatology, 2003 The purpose of the present work was to study the pharmacokinetics of ketorolac, a poorly metabolized drug, in experimental cirrhosis. Cirrhosis was induced by bile duct ligation (BDL) for four weeks in male Wistar rats. Ketorolac was given intravenously (
Liliana Rivera-Espinosa, PhD +5 more
doaj +1 more source
Egyptian Liver Journal, 2021 Background HCV is a major risk factor for HCC; however, the exact mechanism of hepatocarcinogenesis is still not fully understood. Host genetic factors have been reported to play a significant role.
Ghada M. Galal +7 more
doaj +1 more source
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis [PDF]
, 2010 Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin). The Enhanced Liver Fibrosis (ELF) test consists of an
Julie Parkes +12 more
core +2 more sources